What This Apogee Insider Move Might Mean After a 247% Stock Run

Apogee Therapeutics CEO Michael Henderson disposed of 95,046 shares, with 75,046 gifted to charity and 20,000 sold under a pre-established trading plan. Henderson retains 921,000 shares worth ~$123 million. The insider activity is not viewed as a red flag given the CEO's substantial remaining stake. Apogee's lead antibody candidate showed strong Phase 2 data for atopic dermatitis, with Phase 3 trials and head-to-head comparisons against Dupixent expected in late 2026. The company has $1.3 billion in cash funding operations into 2029.